Advanced therapy medicinal products

ATMP Insurance

Advanced therapy medicinal product risks can be more specialist than ordinary pharmaceutical or biotech wording suggests. A review should explain the therapy type, development stage, manufacturing route, clinical involvement and potential severity before market appetite is tested.

Review ATMP insurance appetite Speak to a specialist
Advanced therapy focus Biotech product liability Clinical and manufacturing context

Specialist review before market approach

ATMP insurance review for advanced therapy medicinal product, cell therapy, gene therapy, tissue-engineered product and specialist biotech risks.

Insure24 can help prepare the underwriting story, but cover and terms always depend on the risk details, disclosure, wording, controls and available market appetite.

Who this helps

  • Cell therapy, gene therapy and tissue-engineered product businesses.
  • Biotech companies developing or manufacturing advanced therapy medicinal products.
  • Life science startups moving from R&D into trials, partnerships or production.
  • Businesses that need product liability, clinical trials, D&O, cyber or recall exposures reviewed together.

What markets usually need

  • Therapy type, indication, development stage, trial status and patient population.
  • Manufacturing route, quality controls, cold-chain requirements and outsourcing.
  • Contracts, territories, regulatory pathway, adverse-event procedures and recall or withdrawal planning.
  • Funding stage, board structure, IP, data and insurance requirements from partners or investors.

Market context

  • ATMP appetite depends on the product type, stage, clinical use, manufacturing model and regulatory pathway.
  • The exposure can include R&D, clinical trials, manufacturing, cold chain, product liability and management risk.
  • Markets will usually need a careful narrative rather than a generic biotech label.

Why ATMP deserves a direct route

ATMP buyers use regulated product language that is more precise than broad biotech insurance.

  • Cell and gene therapy risks can carry severe product and trial consequences.
  • Cold chain, manufacturing and clinical dependency need to be described together.
  • Investor and partner requirements may add D&O and financial lines pressure.

Where to link next

This route should reinforce the existing pharmaceutical, life sciences R&D and clinical trials pages.

  • Use pharmaceutical biotech pages for broader biopharma manufacturing.
  • Use clinical trials liability where participant exposure is the immediate issue.
  • Use life sciences D&O where the board and funding exposure is central.

Related specialist routes

Life sciences insuranceReview the related route before sending a complex commercial enquiry to market. Pharmaceutical biotech insuranceReview the related route before sending a complex commercial enquiry to market. Clinical trials liability insuranceReview the related route before sending a complex commercial enquiry to market. Life sciences R&D insuranceReview the related route before sending a complex commercial enquiry to market.

ATMP Insurance FAQs

What does ATMP insurance mean?

It is a specialist insurance review for advanced therapy medicinal product businesses, including cell therapy, gene therapy and tissue-engineered product risks.

Is ATMP insurance the same as biotech insurance?

ATMP risks may sit within biotech, but the product type, clinical pathway, manufacturing controls and severity often need more specific treatment.

What information helps ATMP markets?

Therapy type, development stage, clinical involvement, manufacturing controls, contracts, territories, cold chain, regulatory status and required covers are usually important.

Send the risk for specialist review

Share the activity, cover needed, claims history, contract requirements and any previous market feedback so the enquiry can be triaged properly before approach.

Review ATMP insurance appetite